Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.
CureVac, a Germany-based messenger RNA (mRNA) drug developer spun out of Eberhard Karls University of Tübingen, is floating today in a $213m initial public offering that provides exits for pharmaceutical companies GlaxoSmithKline (GSK), Eli Lilly and Genmab.
The company priced more than 13.3 million shares at the top of the IPO’s $14 to $16 range, valuing it above $2.8bn. It will trade on the Nasdaq Global Market, and Dietmar Hopp, head of majority shareholder Dievini Hopp BioTech, is buying…
